Compare Crispr Therapeutics AG (CRSP) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Open Text Corporation — how do they compare? Crispr Therapeutics AG trades at $53.2 (market cap $4.88B), while Open Text Corporation trades at $23.42 (market cap $5.61B). The key difference: Crispr Therapeutics AG and Open Text Corporation are close in size by market cap, and Open Text Corporation pays a 4.82% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Open Text Corporation for 23 Days on average.
| CRSP | OTEX | |
|---|---|---|
Market Cap | $4.88B | $5.61B |
Volume | 2,861,747 | 1,197,475 |
Sector | Health | Technology |
52-Week High | $74.92 | $39.69 |
52-Week Low | $44.34 | $20.01 |
Typical Hold Time | 77 Days | 23 Days |
Enterprise Value | $3.30B | $10.63B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
OpenText (OTEX) trades at $23.14, up 1.89% today, with strong technical momentum indicated by a bullish overall signal. The company demonstrates robust fundamentals with consistent earnings beats, posting Q2 2026 EPS of $1.23 versus $1.02 expected, and maintains healthy profitability with 12.26% net income margin. Recent corporate actions include a $1 billion senior secured notes offering and strategic AI partnerships, signaling growth initiatives.
The stock presents an attractive valuation opportunity with P/E of 9.01 and P/S of 1.1 below sector averages, supported by analyst consensus target of $28.30 implying 22% upside. Key risks include high debt levels at $6.34 billion and competitive pressures in the software sector. Institutional sentiment remains mixed with 42% buy ratings amid ongoing debt management efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
